Liraglutide in Combination with Metformin or Sulfonylurea for the Treatment of Type 2 Diabetes in Adult Patients
Explore this paper's citation graph
Summary
Liraglutide is demonstrated to be an effective agent in combination with commonly used oral antidiabetic drugs such as metformin and sulphonylureas, with a significant number of patients achieving their glycemic targets without hypoglycemia.
- Type
- article
- Published
- 2012-09-11
- Cited by
- 3
- References
- 42
- Access
- Open access
- OpenAlex
- https://openalex.org/W2074277038
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:72482581
Keywords
Liraglutide, Metformin, Medicine, Hypoglycemia, Sulfonylurea
References
- Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
- Molecular understanding of hyperglycemia's adverse effects for diabetic complications.
- Glycemic Control with Diet, Sulfonylurea, Metformin, or Insulin in Patients with Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS 49)
- Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
- Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.
- Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration.
- The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men
- Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus.
- Five Weeks of Treatment with the GLP-1 Analogue Liraglutide Improves Glycaemic Control and Lowers Body weight in Subjects with Type 2 Diabetes
- Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects.
- Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: U.K. Prospective Diabetes Study (UKPDS 55).
- Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes
- Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005
- Biology of incretins: GLP-1 and GIP.
- Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function
- Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
- Improved glycaemic control with minimal hypoglycaemia and no weight change with the once‐daily human glucagon‐like peptide‐1 analogue liraglutide as add‐on to sulphonylurea in Japanese patients with type 2 diabetes
- Enhancing incretin action for the treatment of type 2 diabetes.
Cited by
- Cardiovascular safety and efficacy of combination therapy with metformin and sodium-glucose cotransporter-2 inhibitors versus metformin and sulfonylureas in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
- Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials
- Predicting responsiveness to GLP-1 pathway drugs using real-world data
Related papers
- Liraglutide + metformin in type 2 diabetes: clinical benefits with early use of liraglutide and switch from sulphonylurea
- Liraglutide + Metformin Combination Therapy in Type 2 Diabetes: Clinical Benefits Associated with Early Use of Liraglutide and with Switching a Sulfonylurea for Liraglutide
- COMPARATIVE EFFICACY OF METFORMIN AND SULFONYLUREA IN MONOTHERAPY OR COMBINATION FOR TYPE 2 DIABETES
- Real-world experience of treatment individualization based on fixed-dose combination of gliclazide extended release+ metformin extended release in type 2 diabetes mellitus
- Pharmacoeconomic aspects of the use of sulfonylurea drugs in type 2 diabetes mellitus
- Effect of new anti-diabetic medications in combination with metformin compared to sulfonylurea in combination with metformin in patients with type 2 diabetes
- For adults with inadequately controlled type 2 diabetes (T2DM), how does metformin-sulfonylurea compare with alternative metformin combinations?
- Secondary sulfonylurea failure : comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide.